EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting CNS myeloid infiltrates provides neuroprotection in a progressive multiple sclerosis model

Tal Ganz, Nina Fainstein, Paschalis Theotokis, Sharona Elgavish, Oriya Vardi-Yaakov, Marva Lachish, Lihi Sofer, Omri Zveik, Nikolaos Grigoriadis, Tamir Ben-Hur

Brain, Behavior, and Immunity · 2024

DOI: 10.1016/j.bbi.2024.08.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2024. Verfasst von Tal Ganz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Hebrew University of Jerusalem, Israel; The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah -…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Disease Models, Animal, Myeloid Cells, Neuroprotection. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Demyelination and axonal injury in chronic-progressive Multiple Sclerosis (MS) are presumed to be driven by a neurotoxic bystander effect of meningeal-based myeloid infiltrates. There is an unmet clinical need to attenuate disease progression in such forms of CNS-compartmentalized MS. The failure of systemic immune suppressive treatments has highlighted the need for neuroprotective and repair-inducing strategies. Here, we examined whether direct targeting of CNS myeloid cells and modulating their toxicity may prevent irreversible tissue injury in chronic immune-mediated demyelinating disease. To that end, we utilized the experimental autoimmune encephalomyelitis (EAE) model in Biozzi mice, a clinically relevant MS model. We continuously delivered intracerebroventricularly (ICV) a retinoic acid receptor alpha agonist (RARα), as a potent regulator of myeloid cells, in the chronic phase of EAE. We assessed disease severity and performed pathological evaluations, functional analyses of immune cells, and single-cell RNA sequencing on isolated spinal CD11b+ cells. Although initiating treatment in the chronic phase of the disease, the RARα agonist successfully improved clinical outcomes and prevented axonal loss. ICV RARα agonist treatment inhibited pro-inflammatory pathways and shifted CNS myeloid cells toward neuroprotective phenotypes without affecting peripheral infiltrating myeloid cell phenotypes, or peripheral immunity. The treatment regulated cell-death pathways across multiple myeloid cell populations and suppressed apoptosis, resulting in paradoxically marked increased neuroinflammatory infiltrates, consisting mainly of microglia and CNS / border-associated macrophages. This work establishes the notion of bystander neurotoxicity by CNS immune infiltrates in chronic demyelinating disease. Furthermore, it shows that targeting compartmentalized neuroinflammation by selective regulation of CNS myeloid cell toxicity and survival reduces irreversible tissue injury, and may serve as a novel disease-modifying approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalDisease Models, AnimalMyeloid CellsNeuroprotectionAnimalsMiceCentral Nervous SystemMice, Inbred C57BLFemaleRetinoic Acid Receptor alphaMultiple SclerosisMultiple Sclerosis, Chronic ProgressiveNeuroprotective Agents

Stichwörter der Autor:innen

CNS-associated MacrophagesExperimental Autoimmune Encephalomyelitis (EAE)MicrogliaNeuroinflammationProgressive Multiple Sclerosis

Substanzen

Retinoic Acid Receptor alphaNeuroprotective Agents

Autor:innen und Institutionen

  • Faculty of Medicine, Hebrew University of Jerusalem, Israel; The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
  • Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece.
  • Info-CORE, Bioinformatics Unit of the 1-CORE, Hebrew University of Jerusalem, Israel.
  • Info-CORE, Bioinformatics Unit of the 1-CORE, Hebrew University of Jerusalem, Israel; Department of Bioinformatics, Jerusalem College of Technology, Israel.
  • Faculty of Medicine, Hebrew University of Jerusalem, Israel; The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah - Hebrew University Medical Center, Jerusalem, Israel. Electronic addre…

Zitieren

APA

Ganz, T., Fainstein, N., Theotokis, P., Elgavish, S., Vardi-Yaakov, O., Lachish, M., Sofer, L., Zveik, O., Grigoriadis, N., & Ben-Hur, T. (2024). Targeting CNS myeloid infiltrates provides neuroprotection in a progressive multiple sclerosis model. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2024.08.032

Vancouver

Ganz T, Fainstein N, Theotokis P, Elgavish S, Vardi-Yaakov O, Lachish M, et al. Targeting CNS myeloid infiltrates provides neuroprotection in a progressive multiple sclerosis model. Brain, Behavior, and Immunity. 2024. doi:10.1016/j.bbi.2024.08.032

BibTeX
@article{Ganz2024,
  author = {Ganz, Tal and Fainstein, Nina and Theotokis, Paschalis and Elgavish, Sharona and Vardi-Yaakov, Oriya and Lachish, Marva and Sofer, Lihi and Zveik, Omri and Grigoriadis, Nikolaos and Ben-Hur, Tamir},
  title = {Targeting CNS myeloid infiltrates provides neuroprotection in a progressive multiple sclerosis model},
  journal = {Brain, Behavior, and Immunity},
  year = {2024},
  doi = {10.1016/j.bbi.2024.08.032}
}
Kostenlos starten →